Medicox "Exclusive Distributor 'Plexens COVID-19 Diagnostic Kit' Applies for MFDS Export Approval"

[Asia Economy Reporter Hyunseok Yoo] Medicox announced on the 14th that Plexense's COVID-19 neutralizing antibody diagnostic kit has applied for export approval from the Ministry of Food and Drug Safety (MFDS). Plexense is a company that develops and manufactures diagnostic kits, and Medicox holds exclusive sales and distribution rights throughout Korea and Europe.

Medicox plans to actively enter overseas markets in cooperation with Plexense as soon as the MFDS export approval process is completed. Plexense's COVID-19 neutralizing antibody diagnostic kit is based on its proprietary enzyme immunoassay diagnostic platform, ACCEL ELISA. Recently, it received favorable reviews from global buyers and diagnostic device developers at MEDICA 2021, the world's largest medical device exhibition held in D?sseldorf, Germany.

Plexense's neutralizing antibody diagnostic kit, which recently obtained European CE certification, enables qualitative diagnosis of the presence of neutralizing antibodies. The company plans to soon release a diagnostic kit capable of quantitatively confirming the generation of neutralizing antibodies and will directly begin overseas certification procedures.

A Medicox official stated, "Through meetings with global companies arranged via various non-face-to-face meetings including the recent medical device exhibition in Germany, Plexense's ACCEL ELISA diagnostic kit platform has demonstrated the potential to be an innovative alternative by providing a faster and more accurate diagnostic process," adding, "Once the export approval application is completed, we will promote and expand overseas business in various ways such as product supply and technical platform partnerships with major overseas diagnostic device developers and diagnostic service labs."

In May, Medicox signed an exclusive distribution agreement to sell and distribute Plexense's COVID-19 diagnostic products domestically and throughout Europe. The strategy is to leverage Medicox's bio business network to enter the global market with Plexense's diagnostic kit products, which have price competitiveness due to lower testing costs compared to existing PCR-based COVID-19 diagnostic kits.

This content was produced with the assistance of AI translation services.